Pharma BD Deal Intelligence
A $20M-upfront licensing deal for a preclinical trispecific T-cell engager, structured almost entirely as a bet on future milestones—Boulevard Bio owes METiS up to $1.6B if MTS-128 clears development and reaches commercial autoimmune-disease sales. Too early-stage to call a win or bust; the payoff hinges entirely on unproven preclinical data advancing through the clinic.
Preclinical trispecific TCE anchoring a new Deerfield-backed immunology player
Full analysis, sources & comparables →METiS TechBio granted Boulevard Bio (a U.S. biotech backed by Deerfield Management) exclusive worldwide rights to develop, manufacture and commercialize MTS-128, a preclinical trispecific T-cell engager designed on METiS's NanoForge AI molecular-engineering platform. Boulevard pays $20 million upfront and up to $1.6 billion in development, regulatory and commercial milestones plus tiered royalties on sales. METiS reports the transaction is the largest disclosed preclinical trispecific TCE out-license on record.
MTS-128 is a preclinical trispecific T-cell engager (TCE) engineered end-to-end on METiS TechBio's NanoForge platform. Trispecific TCEs simultaneously engage multiple targets, intended to improve target-cell killing and broaden activity in autoimmune and immunology indications. The specific lead indication was not disclosed at signing.
Boulevard Bio licenses worldwide rights to MTS-128 (preclinical trispecific TCE) from METiS TechBio for $20M upfront + up to $1.6B milestones plus tiered royalties.
Flagship asset for a Deerfield NewCo; value is almost entirely back-loaded on a preclinical program, so upside is real but early and high-risk.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boulevard Bio, Inc. / METiS TechBio (this deal) | 2026 | $1.6B | 54 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Roche Holding AG / Genentech, Inc. (Roche Group) | 2009 | $46.8B | 72 |
| Travere Therapeutics, Inc. / Everest Medicines Limited | 2026 | $1.1B | 72 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
← Browse all deals · How we score deals
More: 2026 deals · Immunology deals